Health experts still question Dengvaxia-mass vaccination
UNTV News • February 7, 2018 • 3406
MANILA, Philippines – The Senate Blue Ribbon Committee once again questioned the process of procurement of the controversial Dengvaxia vaccines.
For Senate Blue Ribbon Committee chairman, Senator Richard Gordon, there seems to be a manipulation on the procurement of the said vaccines.
The Food and Drug Administration (FDA) and former Health Secretary Janette Garin refuted the allegations.
“I would say that it follows the process po,” FDA Deputy Dir. Gen. for Field regulatory Operations Office Ma. Lourdes Santiago said.
“Because if no CPR (Certificate of Product Registration) is forthcoming, then I will directly inform the president na imposible po ang dengue vaccine (that a dengue vaccine is impossible).” Garin said.
But for some health experts, the mass vaccination of more than 800,000 children is still questionable, as the conduct of such undertaking entails long and thorough preparation.
“I will not take any risk . . . especially on a massive scale,” UP-PGH Dr. Juliet Sio-Aguilar said.
“The patient has the right to know. Hindi nalaman ng tao ‘yan (The public did not know). Prescription based ka, bakit ka magma-mass vaccination (It’s prescription-based, why would you conduct a mass vaccination?),” said health reform advocate, Dr. Anthony Leachon.
On the other hand, health experts believe there is no need to worry for now regarding the effects of Dengavaxia.
“Sa daming kanilang na bakunahan ng Dengvaxia, talagang mayroon at mayroon doon na mga normal diseases that will happen with or without Dengvaxia,” Aguilar said.
( Translation: With the number of people vaccinated with Dengvaxia, there will inevitably be normal diseases that will happen with or without Dengvaxia.)
“Results from the clinical trials . . . in general safe ho,” infectious diseases specialist, Dr. Mary Ann Lansang said.
They said it is premature for them to come up with any conclusion until they have seen the result of the probe conducted by the Dengue Investigative Task Force.
Meanwhile, DOH Secretary Francisco Duque said, the Dengvaxia issue has greatly affected the other government’s Immunization Program.
“And to date, I think it’s down to 57% it’s substantial 30% reduction, that’s truly a cause of concern,” Duque said.
As the hearing rolled on, the Blue Ribbon Committee has issued subpoenas to Public Attorney Office (PAO) Chief Persida Acosta and PAO Forensic Laboratory Director Dr. Erwin Erfe who conducted a separate investigation on the issue.
Some senators are calling for unity on handling the issue to establish an airtight case against the persons involved in the controversy.
“Eh di ba dapat tayo ay magsama-sama, magtulong-tulong? Ang hindi ko maintindihan bakit ayaw nilang makipagtulungan, ano ba ang meron?” said Senate Committee on Health & Demography chairman, Sen. Joseph Victor Ejercito.
(Are we not supposed to work together? I don’t understand why they refuse to cooperate. What’s the reason?)
“Ang ayaw ko lang sa kanila, sinasabi nila Dengvaxia. Hihina ang kaso ng gobyerno kapag sinasabi niyo Dengvaxia tapos wala namang napapatunayan,” Gordon said.
(What I don’t like about them is they keep saying it’s Dengvaxia. The government’s case will weaken if you keep saying Dengvaxia without any proof.)
The Blue Ribbon Committee will set another hearing on the Dengvaxia controversy. – Nel Maribojoc | UNTV News & Rescue
MANILA, Philippines – The Food and Drug Administration (FDA) on Monday (March 30) said it has approved the use of five rapid test kits for novel coronavirus disease (COVID-19) in support of efforts to address the pandemic.
In a statement, the FDA said these point-of-care test kits are registered for use in countries with reliable regulatory agencies such as China and Singapore.
“We approve kits that are registered and used in countries with advanced technology and wide experience with COVID 19,” FDA Director General Eric Domingo said.
Domingo said the rapid test kits will yield a faster result compared with PCR-based kits, but he stressed that its results should be evaluated and interpreted by a trained health professional.
“We have to be very cautious in using these rapid test kits because they measure antibodies and not the viral load itself,” he said.
As a safety precaution, the FDA requires all rapid test kits to have the following product inserts or label: “This product is strictly for medical professional use only and not intended for personal use. The administration of the test and interpretation of results should be done by a trained health professional. Confirmatory testing is required.”
“The body takes time to develop antibodies and this might give a negative result for patients who have been infected but antibodies have not yet developed antibodies,” Domingo said.
“A positive result due to cross reaction with other bacteria or viruses is also possible, which is why a confirmatory PCR based test is still required,” he added.
The FDA also announced it has approved the SARS Cov2 kit by Gene Xpert from Abbott Laboratories.
This PCR-based test kit, the latest in the 17 kits approved for commercial use, can detect the virus within five minutes, according to the agency.
MANILA, Philippines – The Food and Drug Administration (FDA) on Monday (March 30) warned the public against the use of a drug cocktail called ‘Prodex-B’ as an anti-viral treatment for novel coronavirus disease (COVID-19).
In an advisory, the FDA said the drug combination of Procaine and Dexamethasone with Vitamin B or Prodex-B is not registered in the agency.
The FDA issued the warning following “baseless claims” circulating on social media that this drug cocktail has promising effects against viral infections and diseases.
“Procaine is an anesthetic used to reduce pain on injections, while Dexamethasone is a corticosteroid which must be used cautiously due to its side effects including immunosuppression or weaker immune system leading to vulnerability to infections,” the advisory reads.
The FDA said that unregistered drug products have no guaranteed quality, safety and efficacy data which may lead to patient harm.
The agency advised those who may have received Prodex-B to monitor their health condition for any adverse reactions, and such should be given immediate medical attention.
MANILA, Philippines – The Food and Drug Administration (FDA) has relaxed its rules to expedite the release of imported respirators, ventilators and other medical devices which are essential in responding to the novel coronavirus disease (COVID-19) pandemic.
In a letter dated March 23 addressed to Bureau of Customs (BOC) Rey Leonardo Guerrero, FDA Director General Rolando Enrique Domingo advised the bureau that importers of ventilators, respirators, and their respective accessories for commercial purposes need only to present copies of their license to operate.
“On the other hand, foreign donations of ventilators, respirators, and their respective accessories to be used in the treatment of COVID-19 patients need not require FDA clearance prior to customs release,” Domingo said.
“We hope that the measures being introduced would expedite the customs release of ventilators, respirators and their respective accessories which are vital in responding to the threat of COVID-19,” he added.
Foreign Affairs Secretary Teodoro Locsin, Jr. lauded the FDA’s move.
“No more FDA approval needed. No more excuses to delay release from Customs. Thank you all,” he said in a Twitter message which is accompanied by the FDA letter.
A similar rule for commercial imports and foreign donations of personal protective equipment such as face masks and head covers was also issued by the FDA earlier.
UNTV is a major TV broadcast network with 24-hour programming. An Ultra High Frequency station with strong brand content that appeal to everyone, UNTV is one of the most trusted and successful Philippine networks that guarantees wholesome and quality viewing experience.